TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02178722
Drug: INCB024360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily dosing
Study: NCT00442390
Drug: hydrocortisone substitution therapy versus withdrawal
Normalized name: Low-Substituted Hydroxypropyl Cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03193333
Drug: PRO-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posology: 1 drop every 12 hours for 90 days
Study: NCT00679965
Drug: AN2690, 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 90 days and 3 x weekly for 90 days
Study: NCT00679965
Drug: AN2690, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 90 days and 3 x weekly for 90 days
Study: NCT00679965
Drug: AN2690, 7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 90 days and 3 x weekly for 90 days
Study: NCT00679965
Drug: AN2690 Solution Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 90 days and 3x weekly for 90 days
Study: NCT03193333
Drug: Krytantek
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posology: 1 drop every 12 hours for 90 days
Study: NCT02299999
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target: m-TOR
Study: NCT02299999
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target: EGFR
Study: NCT02299999
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target: AKT
Study: NCT02299999
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target: HER2, EGFR
Study: NCT02299999
Drug: Anthracyclines
Normalized name: Anthracyclines and related substances
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA intercalation
Study: NCT02299999
Drug: Taxanes
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target: mitotic tubulin and microtubules
Study: NCT02299999
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alkylating agents
Study: NCT02299999
Drug: DNA intercalators
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA intercalators
Study: NCT02299999
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DNA intercalators
Study: NCT02299999
Drug: vinca alkaloids
Normalized name: Vinca alkaloids and analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target: mitotic tubulin and microtubules
Study: NCT00440557
Drug: Epoetin alfa 3 times weekly /once weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
Study: NCT01572948
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
Study: NCT03603314
Drug: SENS-401
Approvals — FDA: no, EMA: no, PMDA: no
Description: 29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
Study: NCT03603314
Drug: SENS-401
Approvals — FDA: no, EMA: no, PMDA: no
Description: 43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
Study: NCT00183807
Drug: irinotecan, cisplatin, celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02267083
Drug: GPX-150 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
Study: NCT00422747
Drug: beclomethasondipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 100 ug dd for two months, via aerochamber
Study: NCT02114268
Drug: MEDI8897 Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
Study: NCT02114268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo on Day 1.
Study: NCT01941966
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
Study: NCT00716248
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate 6 mg or more per week
Study: NCT02504359
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00944203
Drug: Ipomea pes-caprae ointment
Normalized name: IPOMOEA PES-CAPRAE FLOWERING TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
Study: NCT00196755
Drug: Calcium acetate (PhosLo® )
Normalized name: calcium acetate Oral Capsule [Phoslo]
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium acetate three times per day with each meal
Study: NCT01218113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 3 doses according to protocol schedule
Study: NCT00896246
Drug: Klean-Prep®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four litres of solution administered orally as a divided dose.
Study: NCT00896246
Drug: Moviprep®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two litres of solution administered orally as a divided dose
Study: NCT03855332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overencapsulated placebo
Study: NCT00874237
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato placebo single dose
Study: NCT00874237
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo similar in appearance to moxifloxacin 400 mg
Study: NCT02683837
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03811028
Drug: SOBI003
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly i.v. infusion
Study: NCT01639768
Drug: SUBLIVAC FIX Birch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages to placebo
Study: NCT01988909
Drug: WR 279,396
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin + Gentamicin Topical Cream
Study: NCT01244269
Drug: Placebo 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind gelatin capsule three times daily for a total of 7 doses.
Study: NCT01244269
Drug: Placebo 20
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind gelatin capsule three times daily for a total of 7 doses
Study: NCT01542125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubes were visually identical to the Liposomal Lidocaine tubes.
Study: NCT00951223
Drug: Infergen® (Interferon alfacon-1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
Study: NCT04109183
Drug: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
Study: NCT04961268
Drug: Ibuprofen 600Mg Tab
Normalized name: IBUPROFEN 600MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Study: NCT04961268
Drug: ibuprofen 600 mg/acetaminophen 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Study: NCT04961268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Study: NCT04487392
Drug: Estrogen vaginal cream group (group A)
Normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.
Study: NCT03854929
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis.
Study: NCT03908320
Drug: NRT Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT patch is provided
Study: NCT03111485
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule taken at bedtime
Study: NCT04689204
Drug: CTA30X
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTA30X cell injection by intravenous infusion
Study: NCT01461850
Drug: Neoadjuvant chemotherapy + Interval Debulking Surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
Study: NCT02492477
Drug: blocking with Medunasal®-Heparinblock
Approvals — FDA: no, EMA: no, PMDA: no
Description: blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
Study: NCT01624064
Drug: Calcium Supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 2.5-20 mg/day
Study: NCT01987960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, tablets, orally
Study: NCT00580372
Drug: High-Dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1
Study: NCT02625454
Drug: Intravenous Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Acetaminophen q 6 hours, given intravenously
Study: NCT02625454
Drug: Oral Acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Acetaminophen q 6 hours given orally
Study: NCT02107300
Drug: NeutraSal
Normalized name: NeutraSal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
Study: NCT02569073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo--no drug
Study: NCT03079271
Drug: Lacrisert, 5 Mg Ophthalmic Insert
Normalized name: Lacrisert, 5 mg ophthalmic insert
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05877170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking a placebo in an oral formulation (tablets), to be taken away from meals
Study: NCT04173273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod matching placebo tablet taken by mouth, once daily.
Study: NCT01712620
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
Study: NCT01712620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
Study: NCT00745823
Drug: TRUVADA™
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
Study: NCT01962337
Drug: FPA008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT01962337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT03613545
Drug: probiotics, antibiotics or antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs such as probiotics, antibiotics, antidepressants
Study: NCT02036697
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mcg
Study: NCT04873011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of water will be infused into the stomach in a randomized, double-blinded fashion
Study: NCT00513110
Drug: Caffeine infusion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
Study: NCT00513110
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin 2ng/kg combined with saline infusion (0.9%)
Study: NCT02923388
Drug: Tablet Pyridoxine hydrochloride
Normalized name: pyridoxine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
Study: NCT02923388
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill orally thrice daily for 5 weeks
Study: NCT02781727
Drug: Once weekly subcutaneous injection of TransCon hGH
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly subcutaneous injection
Study: NCT02781727
Drug: Once daily subcutaneous injection of Genotropin
Normalized name: Genotropin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily subcutaneous injection
Study: NCT02282150
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
Study: NCT04759885
Drug: Phase II: NTC015 low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Study: NCT04759885
Drug: Phase II: NTC015 medium dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Study: NCT04759885
Drug: Phase II: NTC015 high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Study: NCT04759885
Drug: Phase III: NTC015 selected dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Study: NCT03435081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01122147
Drug: chamomilla tincture mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient is directed to mouth wash chamomilla tincture lightly three times a day,ten drops for each time,until ulcers completely heal
Study: NCT01122147
Drug: placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient is directed to use placebo mouthwash three times a day, ten drops for each time,until the ulcers completely heal
Study: NCT02242630
Drug: Methylprednisolone, 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compared with intrabursal triamcinolone
Study: NCT00717197
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
Study: NCT01977820
Drug: Sapropterin
Normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
Study: NCT01977820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
Study: NCT00683202
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
Study: NCT00683202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
Study: NCT02242630
Drug: Methylprednisolone, 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compared with intrabursal triamcinolone
Study: NCT03001960
Drug: Preloading before TAVI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preloading with Aspirin and Clopidogrel before TAVI
Study: NCT03001960
Drug: Postloading after TAVI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postloading with Aspirin and Clopidogrel after TAVI
Study: NCT01356849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
Study: NCT04214860
Drug: APR-246
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: APR-246 4.5 g/day
Study: NCT00635167
Drug: Contrast Enhanced-Transrectal Ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline \[Visit 2\]); week 5 (middle of treatment \[Visit 3\]); week 10 (end of treatment \[Visit 4\]); week 18 (2 months after end of EBRT \[Visit 5\]); week 26 (4 months after end of EBRT \[Visit 6\]); and week 36 (6 months after end of EBRT \[Visit 7\]).
Study: NCT02262117
Drug: specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
Study: NCT03006432
Drug: 5Fluorouracil bolus
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03006432
Drug: 5Fluorouracil continu
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04410731
Drug: Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy
Normalized name: CANINE ALLOGENEIC FREEZE-DRIED PLATELET-RICH PLASMA 400000000 in 1 mL INTRA-ARTICULAR INJECTION, POWDER, FOR SUSPENSION [PrecisePRP Canine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bilateral intra-articular injection of manufactured cell cultured expanded allogeneic BM-MSCs for painful lumbar facet joint arthropathy
Study: NCT02067195
Drug: Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hydration for patients without chronic kidney disease(CrCl\<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
Study: NCT01874756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 placebo capsules daily for 8 weeks
Study: NCT01874756
Drug: LY500307 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks
Study: NCT04078568
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
Study: NCT02067195
Drug: 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP \<13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and \>1.5 ml/kg/hr for LVEDP \>18 mmHg, whereas,0.5 ml/kg/hr for LVEDP \>20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
Study: NCT01398020
Drug: Standard Bowel Prep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to take 4L of Peglyte the day prior to procedure.
Study: NCT02109562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.